Linda Surh and David Laurie et al discuss regulatory moves to incorporate pharmacogenomic analysis in the drug development process.
Pharmacogenomic (PGx) analysis – the study of how variations in the human genome affect individuals’ response to medications – is becoming an increasingly important component of drug development...
Please login to read the full article.
